Saxonov Serge 4

4 · 10x Genomics, Inc. · Filed Mar 4, 2025

Form 4

Period: 2025-02-28

DirectorChief Executive Officer

Transactions

Sale
Class A Common Stock
2025-02-28$10.63/sh−7,942$84,393→ 871,540 total
Exercise/Conversion
Stock Option (right to buy)
2025-03-04−50,000→ 17,463 total
Exercise: $1.20Exp: 2027-10-18→ Class A Common Stock (50,000 underlying)
Exercise/Conversion
Class A Common Stock
2025-03-04$1.20/sh+50,000$60,000→ 921,540 total

Holdings

Footnotes (7)

[F1]The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 12, 2024 and terminated effective March 4, 2025.
[F2]This transaction was executed in multiple trades at prices ranging from $10.415 to $10.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
[F3]The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
[F4]The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
[F5]The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
[F6]The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
[F7]This option, originally for 300,000 shares, of which 282,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021.

Documents

1 file